An experimental combination of two drugs halts the progression of small cell lung cancer, the deadliest form of lung cancer, according to a recent study. The discovery was made by researchers at Washington University School of Medicine in St Louis, Grenoble Alpes University in Grenoble in France, and The University… Read More
Investment from Takeda ventures will fund the development of Zelluna Immunotherapy’s allogeneic T Cell Receptor Natural Killer (TCR-NK) cells for the treatment of cancer. The funds will enable the advancement of a lead TCR-NK product through manufacturing to Clinical Trial Application (CTA) / Investigational New Drug Application (IND) readiness and,… Read More
The European Commission (EC) has approved orphan drug Scemblix (asciminib), providing a new treatment option for patients who are intolerant or resistant to tyrosine kinase inhibitors (TKIs). It is approved to treat adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase who have been previously treated with two or more… Read More
A study led by LSU Health New Orleans cancer researchers describes a novel therapeutic strategy to overcome tumour-induced immunosuppression. For the first time, the research team identified a critical immunosuppressive pathway and a promising approach to intervene, protecting the ability of T-cells to attack cancer cells. Results are published in… Read More
The European Medicines Agency (EMA) has granted a Marketing Authorisation Application (MAA) for a combination treatment targeting adults with acute myeloid leukaemia (AML) who are not candidates for standard induction chemotherapy. The MMA was granted to Otsuka Pharmaceutical and Astex Pharmaceuticals’ oral fixed-dose combination of decitabine and cedazuridine (ASTX727). The… Read More
The drug discovery sector is working to address cancer disparities. Anita Ramanathan examines the importance of inclusivity and diversity throughout the drug discovery and development process. While the risk of cancer is universal, some groups are disproportionately affected by cancer compared to others. Disparities resulting from genetic, environmental, social, and… Read More
A precision medicine for early-stage breast cancer has been approved by the European Medicines Agency (EMA). Developed by AstraZeneca and Merck & Co (MSD) under the brand name Lynparza, the treatment is a precision medicine which blocks DNA damage response (DDR) in cells or tumours that have… Read More
Listen to this article on the DDW Podcast: By Mark White, Associate Director of Biopharma Product Marketing at Bio-Rad and Marwan Alsarraj, Biopharma Segment Manager, Digital Biology Group. Until about 25 years ago, the best treatment option for someone with blood cancer was either toxic radiation and chemotherapy or a bone… Read More
Scientists have discovered how melanoma skin cancer cells invade new tissues in research they hope might lead to new treatments. A team from The Institute of Cancer Research, London discovered that melanoma cells harness a gene usually used by growing nerves to escape from their immediate area… Read More
Scientists modelling the cancer-suppressing p53 gene identify how the 20 different molecules unique to elephants get activated for increased sensitivity and response against carcinogenic conditions – with implications for cancer treatments in humans. Scientists from seven research institutions including the University of Oxford and the University of Edinburgh have used… Read More
The size of tumour and immune cell populations and their interactions over time impact outcomes to treatment. Immunotherapies that activate the immune system to seek and kill cancer cells have greatly improved outcomes for many patients with solid tumours. There is still, however, a subset of patients who do not… Read More
This 26-page DDW eBook, sponsored by The Jackson Laboratory, contains exclusive insight from industry experts on: How machine learning is currently used across different stages of cancer research Accelerating research: the path forward for treating rare cancers Immunotherapy challenges and the tools for research Why combination immunotherapies are one… Read More
The National Institute for Health and Care Excellence (NICE) has overturned a previous decision where it chose not to recommend the immunotherapy BAVENCIO (avelumab) for the treatment of bladder cancer. The decision comes after avelumab’s developers, Merck KGaA and Pfizer, appealed the prior Final… Read More
DDW Deputy Editor Reece Armstrong takes a look at some of the biggest developments that took place within oncology this week (4 April – 8 April). Scientists win award for transforming breast cancer treatment A team of scientists from The Institute of Cancer Research, London,… Read More
Biotechnology company RedX is collaborating with the Garvan Institute of Medical Research on a project investigating novel therapeutic targets in cancer-associated fibrosis. The collaboration aims to better understand treatments that could lead to increased patient survival in currently very poorly treated highly fibrotic cancers, such as… Read More
A new research centre has been established in London to help discover new approaches to treating cancer. The Centre for Protein Degradation will be based in The Institute of Cancer Research (ICR) in London and will focus on targeted protein degradation to help researchers discover new… Read More
